Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA)

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best strong buy stocks to invest in under $5. Needham maintained a bullish outlook on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) on January 6, reiterating a Buy rating on the stock with a $10 price target. The rating update came the same day Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced the dosing of the first patient in the REVEAL pivotal trial evaluating TSHA-102 in Q4 2025, with enrollment advancing across multiple sites. It reported progress across the TSHA-102 pivotal program, an intrathecally delivered AAV9 gene therapy with disease-modifying potential, in clinical evaluation for the treatment of Rett syndrome.

The company also stated that it reached written alignment with the FDA regarding the inclusion of ≥3 months of safety data from the ASPIRE trial evaluating TSHA-102 in the planned BLA submission to support a broad label in patients aged ≥2 years with Rett syndrome. Dosing in the REVEAL pivotal trial and ASPIRE trial is anticipated to be completed in Q2 2026, with the longer-term safety and efficacy data update from Part A of REVEAL Phase 1/2 trials expected in H1 2026.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company that develops and commercializes adeno-associated virus (AAV) based gene therapies to treat monogenic diseases of the central nervous system.

While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.